Theseus Pharmaceuticals Inc (NAS:THRX)
$ 4.06 0 (0%) Market Cap: 181.28 Mil Enterprise Value: -20.19 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 24/100

Theseus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2022 / 08:30PM GMT
Release Date Price: $6.01 (+5.81%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

(technical difficulty) , one of the biotech analysts at Jefferies. And I'm happy to introduce our guest today, Tim Clackson, who is the CEO of Theseus. Thanks so much for joining us today, Tim.

Timothy P. Clackson
Theseus Pharmaceuticals, Inc. - CEO, President & Director

It's a pleasure to be here, Maury.

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

And we're going to do a fireside chat format. So maybe for those who may be new to the story, if you can provide a 1-minute intro to Theseus.

Timothy P. Clackson
Theseus Pharmaceuticals, Inc. - CEO, President & Director

Happy to. So Theseus is a pure precision oncology company. And we're focusing on one particular kind of TKI that we think is crucial for success. And that is what we call a covariant inhibitor. That's an inhibitor that's able to inhibit any of the resistance mutations that occur on a oncogenic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot